These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 34616699)

  • 21. Infant Exposure to Dolutegravir Through Placental and Breast Milk Transfer: A Population Pharmacokinetic Analysis of DolPHIN-1.
    Dickinson L; Walimbwa S; Singh Y; Kaboggoza J; Kintu K; Sihlangu M; Coombs JA; Malaba TR; Byamugisha J; Pertinez H; Amara A; Gini J; Else L; Heiberg C; Hodel EM; Reynolds H; Myer L; Waitt C; Khoo S; Lamorde M; Orrell C;
    Clin Infect Dis; 2021 Sep; 73(5):e1200-e1207. PubMed ID: 33346335
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modelling.
    Bunglawala F; Rajoli RKR; Mirochnick M; Owen A; Siccardi M
    J Antimicrob Chemother; 2020 Mar; 75(3):640-647. PubMed ID: 31860112
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Impact of Dolutegravir-Based Antiretroviral Therapy on Piperaquine Exposure following Dihydroartemisinin-Piperaquine Intermittent Preventive Treatment of Malaria in Pregnant Women Living with HIV.
    Banda CG; Nkosi D; Allen E; Workman L; Madanitsa M; Chirwa M; Kapulula M; Muyaya S; Munharo S; Tarning J; Phiri KS; Mwapasa V; Ter Kuile FO; Maartens G; Barnes KI
    Antimicrob Agents Chemother; 2022 Dec; 66(12):e0058422. PubMed ID: 36374096
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estimating fetal exposure to the P-gp substrates, corticosteroids, by PBPK modeling to inform prevention of neonatal respiratory distress syndrome.
    Anoshchenko O; Milad MA; Unadkat JD
    CPT Pharmacometrics Syst Pharmacol; 2021 Sep; 10(9):1057-1070. PubMed ID: 34273255
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model II: Verification of the model for passive placental permeability drugs.
    Zhang Z; Unadkat JD
    Drug Metab Dispos; 2017 Aug; 45(8):939-946. PubMed ID: 28049636
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions.
    Greupink R; Schreurs M; Benne MS; Huisman MT; Russel FG
    Eur J Pharm Sci; 2013 Aug; 49(5):819-28. PubMed ID: 23806476
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK.
    Rajoli RKR; Flexner C; Chiong J; Owen A; Donnelly RF; Larrañeta E; Siccardi M
    Eur J Pharm Biopharm; 2019 Nov; 144():101-109. PubMed ID: 31525446
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predicting Human Fetal Drug Exposure Through Maternal-Fetal PBPK Modeling and In Vitro or Ex Vivo Studies.
    Balhara A; Kumar AR; Unadkat JD
    J Clin Pharmacol; 2022 Sep; 62 Suppl 1(Suppl 1):S94-S114. PubMed ID: 36106781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lopinavir/ritonavir: a review of its use in the management of HIV infection.
    Cvetkovic RS; Goa KL
    Drugs; 2003; 63(8):769-802. PubMed ID: 12662125
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of the betamethasone and dexamethasone dosing regimen during pregnancy: a combined placenta perfusion and pregnancy physiologically based pharmacokinetic modeling approach.
    Van Der Heijden JEM; Van Hove H; Van Elst NM; Van Den Broek P; Van Drongelen J; Scheepers HCJ; De Wildt SN; Greupink R
    Am J Obstet Gynecol; 2024 May; ():. PubMed ID: 38763343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Using mechanistic physiologically-based pharmacokinetic models to assess prenatal drug exposure: Thalidomide versus efavirenz as case studies.
    Atoyebi SA; Rajoli RKR; Adejuyigbe E; Owen A; Bolaji O; Siccardi M; Olagunju A
    Eur J Pharm Sci; 2019 Dec; 140():105068. PubMed ID: 31518681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Expansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19.
    Ke AB; Nallani SC; Zhao P; Rostami-Hodjegan A; Unadkat JD
    Br J Clin Pharmacol; 2014 Mar; 77(3):554-70. PubMed ID: 23834474
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
    Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physiologically Based Pharmacokinetic Modeling in Pregnant Women Suggests Minor Decrease in Maternal Exposure to Olanzapine.
    Zheng L; Yang H; Dallmann A; Jiang X; Wang L; Hu W
    Front Pharmacol; 2021; 12():793346. PubMed ID: 35126130
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An Application of a Physiologically Based Pharmacokinetic Approach to Predict Ceftazidime Pharmacokinetics in a Pregnant Population.
    Abduljalil K; Gardner I; Jamei M
    Pharmaceutics; 2024 Mar; 16(4):. PubMed ID: 38675135
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies.
    Aboud M; Orkin C; Podzamczer D; Bogner JR; Baker D; Khuong-Josses MA; Parks D; Angelis K; Kahl LP; Blair EA; Adkison K; Underwood M; Matthews JE; Wynne B; Vandermeulen K; Gartland M; Smith K
    Lancet HIV; 2019 Sep; 6(9):e576-e587. PubMed ID: 31307948
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses.
    Zhang Z; Imperial MZ; Patilea-Vrana GI; Wedagedera J; Gaohua L; Unadkat JD
    Drug Metab Dispos; 2017 Aug; 45(8):920-938. PubMed ID: 28588050
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.